封面
市場調查報告書
商品編碼
927806

肝腎症候群治療的全球市場:成長,趨勢,預測(2020年~2025年)

Hepatorenal Syndrome Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

肝腎症候群治療市場在預測期間內預計將以全體年複合成長率約6.2%成長。肝腎綜合徵是一種在嚴重肝損害的人中發現的一種進行性腎功能衰竭,最常由肝硬化引起。當腎臟衰竭時,毒素開始在體內蓄積並最終導致肝衰竭。促進市場增長的主要因素是肝損害和肝硬化的患病率增加。根據疾病控制與預防中心的數據,僅在美國,2018年就有450萬成年人被診斷出患有慢性肝病。此外,更多的快速通道和孤兒藥名稱將推動市場增長。但是,藥品的嚴格監管要求和副作用限制了市場的增長。

本報告提供全球肝腎症候群治療市場調查,提供市場概要,各不同治療·各地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 肝腎症候群相連的重度的肝損傷的盛行率增加
    • Fast Track和罕見疾病用醫藥品的增加
  • 阻礙市場要素
    • 藥物使用相關的副作用和風險
    • 嚴格法規必要條件
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場區隔

  • 不同治療
    • 肝臟移植
    • 手術分流
    • 腎替代療法
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Cumberland Pharmaceuticals Inc.
    • Mallinckrodt Pharmaceuticals
    • New Medicon Pharma Lab
    • Becton, Dickinson and Company
    • Edwards Lifesciences Corporation
    • Aetna Inc.
    • Baxter
    • Fuji Systems Corp
    • Johnson & Johnson Co
    • G Surgiwear Ltd

第7章 市場機會及未來趨勢

簡介目錄
Product Code: 68344

The hepatorenal syndrome treatment market is projected to record a CAGR of nearly 6.2% over the forecast period. Hepatorenal syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. As the kidneys stop functioning, toxins begin to build up in the body. Eventually, this leads to liver failure. The major factor attributing to the growth of the market is the increase in the prevalence of liver damage and cirrhosis. According to the Centers for Disease Control and Prevention, 4.5 million adults are diagnosed with chronic liver disease in the year 2018, in the United States alone. Furthermore, increasing fast-track and orphan drug designations boosts the market growth. However, side effects with the drugs and stringent regulations are restraining the market growth.

Key Market Trends

Therapuetics Segment is the Fastest Growing Segment of the Hepatorenal Syndrome Treatment Market.

The therapeutics segment is expected to grow at a greater phase as the patients prefer taking drugs than undergoing surgeries. Furthermore, increasing fast track and orphan designations to the drugs is further boosting the segment. Several drugs have received orphan drug designation, thereby accelerating their approval process, and this can act as a factor pushing the growth of the therapeutics segment. For instance, in November 2018, BioVie Inc. announced that the FDA granted Orphan Drug designation to its Terlipressin drug for the treatment of the hepatorenal syndrome. The designation for orphan drugs allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials, along with seven years of market exclusivity upon regulatory approval. This is likely to drive the hepatorenal syndrome treatment market during the forecast period.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors, such as the presence of key players, established healthcare infrastructure, increased prevalence of severe liver damage and cirrhosis are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to the US Department of Health and Human Services,1 in 400 adults in the United States has cirrhosis for the year 2018. As per the statistics the increasing patient pool and increasing disposable revenue in this country boost the market growth of the region.

Competitive Landscape

The hepatorenal syndrome treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, New Medicon Pharma Lab, Becton, Dickinson and Company, Edwards Lifesciences Corporation, Aetna Inc.,Baxter, Fuji Systems Corp, Johnson & Johnson Co, G Surgiwear Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Severe Liver Damage Which Often Leads to Hepatorenal Syndrome
    • 4.2.2 Increasing Fast Track and Orphan Drug Designations
  • 4.3 Market Restraints
    • 4.3.1 Side-effects and Risks Related to Drug Usage
    • 4.3.2 Stringent Regulatory Requirements
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Therapeutics
    • 5.1.2 Liver Transplantation
    • 5.1.3 Surgical Shunting
    • 5.1.4 Renal Replacement Therapy
    • 5.1.5 Other Treatments
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Cumberland Pharmaceuticals Inc.
    • 6.1.2 Mallinckrodt Pharmaceuticals
    • 6.1.3 New Medicon Pharma Lab
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Edwards Lifesciences Corporation
    • 6.1.6 Aetna Inc.
    • 6.1.7 Baxter
    • 6.1.8 Fuji Systems Corp
    • 6.1.9 Johnson & Johnson Co
    • 6.1.10 G Surgiwear Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS